Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OS001 is a low-dose atropine sulfate eye drop formulation (available in 0.01% and 0.02% concentrations) developed by Seefunge Pharmaceutical Technology for the treatment of myopia in children and adolescents. Atropine is a non-selective muscarinic acetylcholine receptor antagonist. In the context of myopia, it is used topically to slow the progression of the condition, specifically by inhibiting axial elongation of the eye. The drug is currently being evaluated in a randomized, double-blind, multicenter Phase III clinical trial to assess its long-term efficacy and safety over a 96-week period compared to placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OS001 (Seefunge (Suzhou) Pharmaceutical Technology Co., Ltd.).